The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

During his time in Columbus, Dr. Miller published an illustrated book, “Principles of Health Preservation”, which observed ...

Paul Howe, chief commercial officer at Protega Pharma, discusses how regulatory agencies are updating their policies based on the presence of abuse-deterrent medications.

Kylie Jenner has battled rumors about plastic surgery and her changing appearance ever since fans watched her grow up and blossom on her family’s former reality show, Keeping Up With the ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and ...

†High patient compliance after training. ‡Likely to be preferred for frail patients. Adapted from [34].

Previously, EGFR mutation-positive NSCLC patients relied on chemotherapy to prevent cancer recurrence after surgery, according to the foundation. “I am pleased we have been able to recommend ...